Thalassemia

Disclaimer: This information is intended for healthcare professionals as a comprehensive clinical reference and is based on current medical knowledge and guidelines. It is not a substitute for professional medical judgment. Patient care decisions must always be made in the context of individual patient circumstances, clinical findings, and available evidence. Consult with relevant specialists and refer to the most current local guidelines.

Overview

• Definition: Thalassemia is a group of inherited blood disorders characterized by a reduced or absent synthesis of one or more globin chains of hemoglobin. This imbalance leads to ineffective erythropoiesis, chronic hemolytic anemia, and varying degrees of tissue hypoxia. It is a quantitative hemoglobinopathy, distinct from qualitative hemoglobinopathies like sickle cell disease.
• Epidemiology: Thalassemia is one of the most common single-gene disorders globally, particularly prevalent in regions where malaria is or was endemic, including the Mediterranean basin, Middle East, Indian subcontinent, Southeast Asia, and parts of Africa.
  • Globally, an estimated 1.5% of the population are carriers for alpha- or beta-thalassemia traits.
  • Carrier rates can exceed 10% in some populations (e.g., Cyprus for beta-thalassemia, Southeast Asia for alpha-thalassemia).
  • Approximately 60,000 to 100,000 infants are born annually with severe forms of thalassemia.

• Classification: Thalassemia is classified based on the type of globin chain synthesis that is affected.

  • Alpha-Thalassemia (α-Thalassemia): Involves the alpha-globin genes, located on chromosome 16. Humans typically have four alpha-globin genes (two on each chromosome 16).

    • Silent Carrier (–α/αα): Deletion of one alpha-globin gene. Clinically asymptomatic. Normal hematology or very mild microcytosis.
    • Alpha-Thalassemia Trait (α-Thalassemia Minor):
      • cis deletion (– –/αα): Deletion of two alpha-globin genes on the same chromosome (common in Southeast Asia).
      • trans deletion (–α/–α): Deletion of two alpha-globin genes on opposite chromosomes (common in African populations).
      • Mild microcytic, hypochromic anemia (MCV 70-80 fL), often asymptomatic.
    • Hemoglobin H (Hb H) Disease (– –/–α): Deletion of three alpha-globin genes. Forms beta-globin tetramers (Hb H), which are unstable and precipitate.
      • Moderately severe microcytic, hypochromic anemia (Hb 7-10 g/dL), splenomegaly, jaundice, bone changes. Variable transfusion dependence.
    • Hb Bart's Hydrops Fetalis (– –/– –): Deletion of all four alpha-globin genes. Forms gamma-globin tetramers (Hb Bart's), which have very high oxygen affinity, leading to severe tissue hypoxia.
      • Incompatible with life; usually results in stillbirth or neonatal death shortly after birth due to severe hydrops fetalis, ascites, and anasarca. Significant maternal complications (e.g., pre-eclampsia, hemorrhage).

  • Beta-Thalassemia (β-Thalassemia): Involves the beta-globin genes, located on chromosome 11. Humans typically have two beta-globin genes (one on each chromosome 11). Mutations (point mutations or small deletions/insertions) reduce (β+) or abolish (β0) beta-globin synthesis.

    • Beta-Thalassemia Minor (Beta-Thalassemia Trait): Heterozygous for a beta-thalassemia mutation (β/β+ or β/β0).
      • Mild microcytic, hypochromic anemia (MCV 60-75 fL), often asymptomatic. Characterized by elevated Hb A2 (>3.5%) and sometimes mildly elevated Hb F.
    • Beta-Thalassemia Intermedia: Varies from mild to severe, typically presenting later in childhood or adulthood and requiring only occasional or no blood transfusions.
      • Genotypes include homozygous β+ mutations, compound heterozygosity for a β+ and a silent β-mutation, or co-inheritance of alpha-thalassemia with severe beta-thalassemia.
      • Hb typically 6-10 g/dL. Patients may develop splenomegaly, bone changes, and iron overload.
    • Beta-Thalassemia Major (Cooley's Anemia): Homozygous or compound heterozygous for severe beta-thalassemia mutations (β0/β0 or β+/β0).
      • Severe transfusion-dependent anemia (Hb < 7 g/dL) presenting within the first year of life. Untreated, leads to death in early childhood.

  • Other Thalassemia Syndromes:

    • Delta-Beta Thalassemia: Reduced or absent delta and beta globin chain synthesis. Often milder.
    • Hemoglobin E/Beta-Thalassemia: Compound heterozygosity for Hb E (a structural variant with reduced synthesis) and beta-thalassemia. Severity ranges from intermedia to major.
    • Lepore Hemoglobinopathies: Fusion globin chain combining delta and beta sequences.

Pathophysiology

• Mechanism: The fundamental defect is a reduced or absent synthesis of a specific globin chain (alpha or beta), leading to an imbalance in the production of alpha and non-alpha (beta, gamma, delta) globin chains.
  1. Globin Chain Imbalance: In beta-thalassemia, excess alpha chains precipitate within erythroid precursors and mature red blood cells. In alpha-thalassemia (e.g., Hb H disease), excess beta chains form unstable tetramers (Hb H).
  2. Ineffective Erythropoiesis: The precipitated globin chains are toxic to erythroid precursors in the bone marrow, leading to premature destruction of these cells. This results in intramedullary hemolysis and ineffective erythropoiesis, meaning fewer mature red blood cells are released into circulation despite increased bone marrow activity.
  3. Hemolysis: The abnormal red blood cells that do manage to leave the bone marrow are rigid and damaged, leading to accelerated destruction by the reticuloendothelial system, primarily in the spleen. This extravascular hemolysis contributes to chronic anemia.
  4. Anemia and Hypoxia: The combined effect of ineffective erythropoiesis and hemolysis results in severe anemia and tissue hypoxia.
  5. Compensatory Mechanisms: The body attempts to compensate for chronic anemia by:
     • Increased Erythropoiesis: Marrow expansion, leading to bone deformities (facial, skull), and extramedullary hematopoiesis (e.g., spleen, liver, paraspinal masses).
     • Increased Iron Absorption: Chronic anemia and ineffective erythropoiesis lead to suppression of hepcidin (a key iron-regulating hormone), resulting in inappropriately high gastrointestinal iron absorption, contributing to iron overload even without transfusions.
  6. Iron Overload: For transfusion-dependent thalassemia (TDT), repeated blood transfusions (each unit contains ~200-250 mg iron) are the primary cause of iron overload. Iron accumulates in various organs, including the heart, liver, endocrine glands, and pancreas, leading to organ damage and dysfunction (e.g., cardiomyopathy, cirrhosis, diabetes, hypogonadism).
• Risk Factors:
  • Genetic Inheritance: Autosomal recessive inheritance. Having one or two affected parents increases the risk.
  • Ethnic Background: Higher prevalence in populations from the Mediterranean, Middle East, Indian subcontinent, Southeast Asia, and parts of Africa.
  • Consanguinity: Marriages between close relatives increase the risk of offspring inheriting two copies of the same recessive gene mutation.
• Protective Factors: There are no known protective factors against inheriting the genetic mutations causing thalassemia. However, genetic counseling and prenatal diagnosis can help prevent the birth of affected individuals in high-risk couples.

Clinical Presentation

Signs and Symptoms

• Cardinal Features: Vary significantly based on the type and severity of thalassemia.
  • Anemia: Fatigue, pallor, weakness, dyspnea on exertion.
  • Jaundice: Due to chronic hemolysis.
  • Growth Failure: Especially in severe, untreated forms.
  • Bone Deformities: Frontal bossing, maxillary hyperplasia ("chipmunk" facies), due to marrow expansion.
  • Hepatosplenomegaly: Enlargement of liver and spleen due to extramedullary hematopoiesis and increased RBC destruction.
  • Iron Overload Symptoms: If inadequately chelated, cardiac dysfunction (shortness of breath, palpitations, edema), liver dysfunction (abdominal pain, ascites), endocrine dysfunction (delayed puberty, diabetes, hypothyroid).
• Early Signs:
  • Beta-Thalassemia Major: Typically manifests between 3-6 months of age (when gamma-globin switches to beta-globin production), presenting with:
    • Severe pallor, irritability, poor feeding, failure to thrive.
    • Gradual onset of hepatosplenomegaly.
    • Recurrent infections.
  • Hb H Disease: Usually presents in early childhood or later with chronic hemolytic anemia, occasional jaundice, or splenomegaly. Symptoms may worsen during infections.
• Advanced Signs:
  • Severe bone deformities (frontal bossing, prominent malar eminences, maxillary overgrowth, dental malocclusion, "hair-on-end" appearance on skull X-ray).
  • Leg ulcers (non-healing, often on the lower shin).
  • Gallstones (pigmented, due to chronic hemolysis).
  • Endocrine dysfunction: Growth retardation, delayed or absent puberty, hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism, adrenal insufficiency.
  • Cardiac complications: Arrhythmias, cardiomyopathy, congestive heart failure (leading cause of death from iron overload).
  • Liver cirrhosis and failure.
  • Pulmonary hypertension.
• Atypical Presentations:
  • Silent carriers and Thalassemia Trait: Usually asymptomatic. May present with mild microcytic anemia found incidentally on routine blood tests. Often misdiagnosed as iron deficiency.
  • Thalassemia Intermedia: Highly variable. May be asymptomatic for many years, then develop symptoms in adulthood (e.g., fatigue, splenomegaly, leg ulcers, gallstones, mild bone changes) or become transfusion-dependent during times of stress (infection, pregnancy). Iron overload can develop even without transfusions due to increased GI absorption.

Physical Examination

• Inspection:
  • Pallor: Conjunctival, mucosal, skin.
  • Jaundice: Scleral icterus, yellowish skin.
  • Facial and Skeletal Changes: Frontal bossing, prominent cheekbones (malar eminences), flattened nasal bridge, malocclusion ("chipmunk facies"). Short stature.
  • Abdominal Distension: Due to hepatosplenomegaly.
  • Skin: Generalized bronze hyperpigmentation (hemochromatosis), leg ulcers (often pretibial), particularly in non-transfusion-dependent forms.
• Palpation:
  • Abdomen: Massive splenomegaly (firm, non-tender), hepatomegaly (firm, non-tender).
  • Cardiac: Signs of cardiac iron overload: tachycardia, gallop rhythm, murmurs (flow murmurs from anemia, or signs of valvular dysfunction/cardiomyopathy).
• Special Tests:
  • No specific "special tests" for thalassemia diagnosis during physical exam, but a comprehensive systemic examination will reveal the extent of organ involvement.
  • Neurological exam may reveal signs of extramedullary hematopoiesis compressing the spinal cord (rare).
  • Ophthalmoscopy for signs of retinopathy (less common than in sickle cell).

Diagnostic Approach

History Taking

• Key Questions:
  • Family History: Any family members with anemia, jaundice, splenectomy, or diagnosed thalassemia/hemoglobinopathy? (Crucial, as it's an inherited disorder).
  • Ethnic Origin: Are the parents or grandparents from high-prevalence regions (Mediterranean, Middle East, Asia)?
  • Age of Onset of Symptoms: When did pallor, fatigue, or other symptoms first appear? (Helps differentiate major from intermedia).
  • Transfusion History: Has the patient ever received blood transfusions? How often? (Indicates severity and need for iron chelation).
  • Growth and Development: Any growth delay, pubertal delay, or other endocrine symptoms?
  • Other Symptoms: Jaundice, abdominal pain (gallstones, splenomegaly), bone pain/fractures, leg ulcers, shortness of breath, palpitations.
  • Prior Diagnoses/Treatments: Was iron deficiency anemia ever diagnosed or treated? (Crucial to avoid inappropriate iron supplementation).
  • Complications: History of specific organ involvement (e.g., heart failure, diabetes, liver disease, infections).
• Red Flags:
  • Severe microcytic, hypochromic anemia unresponsive to iron supplementation.
  • Unexplained hepatosplenomegaly, especially in early childhood.
  • Family history of severe anemia or hydrops fetalis.
  • Persistent pallor and failure to thrive in infancy, particularly after 3-6 months of age.
  • Bone changes (frontal bossing, maxillary prominence).

Laboratory Tests

• First-Line:
  • Complete Blood Count (CBC) with Differential:
    • Microcytic Hypochromic Anemia: Mean Corpuscular Volume (MCV) typically < 80 fL, Mean Corpuscular Hemoglobin (MCH) < 27 pg.
    • Red Blood Cell (RBC) Count: Often normal or paradoxically elevated despite low Hb (due to ineffective erythropoiesis, unlike iron deficiency where RBC count is low). RBC > 5.0 x 10^12/L in relation to low MCV and Hb is highly suggestive of thalassemia trait.
    • Red Cell Distribution Width (RDW): Often normal in thalassemia trait, whereas it is usually elevated in iron deficiency.
  • Peripheral Blood Smear:
    • Target Cells: Characteristic.
    • Teardrop Cells, Basophilic Stippling.
    • Anisopoikilocytosis (variation in cell size and shape).
    • Nucleated Red Blood Cells (NRBCs): Present in severe forms (beta-thalassemia major), indicative of stressed erythropoiesis.
  • Reticulocyte Count: Usually elevated in thalassemia (reflects compensatory erythropoiesis).
  • Iron Studies (Serum Iron, Total Iron Binding Capacity [TIBC], Ferritin):
    • Essential to differentiate from iron deficiency anemia.
    • Thalassemia Trait/Intermedia: Serum iron and ferritin are typically normal or elevated; TIBC is normal or decreased.
    • Transfusion-Dependent Thalassemia: Ferritin is typically very high (>1000 ng/mL) reflecting iron overload.
• Confirmatory:
  • Hemoglobin Electrophoresis or High-Performance Liquid Chromatography (HPLC):
    • Beta-Thalassemia Minor: Increased Hb A2 (>3.5%), often mildly increased Hb F (1-5%). Hb A is predominant.
    • Beta-Thalassemia Major: Absent or very low Hb A, significantly elevated Hb F (often >90%), variable Hb A2.
    • Beta-Thalassemia Intermedia: Variable Hb A, elevated Hb F (20-80%), increased Hb A2.
    • Hb H Disease: Presence of a fast-migrating Hb H band (beta-globin tetramers). Hb Barts may also be present.
    • Alpha-Thalassemia Trait/Silent Carrier: Normal Hb electrophoresis (no abnormal Hb detectable).
  • DNA Analysis (Molecular Genetic Testing):
    • Gold Standard for Alpha-Thalassemia: Detection of alpha-globin gene deletions or point mutations (e.g., by multiplex PCR, MLPA). Necessary for definitive diagnosis of alpha-thalassemia.
    • For Beta-Thalassemia: Used to identify specific beta-globin gene mutations, particularly useful in prenatal diagnosis, genetic counseling, or when Hb electrophoresis results are ambiguous.
• Monitoring:
  • CBC: To monitor anemia and transfusion requirements.
  • Reticulocyte Count: To assess bone marrow activity.
  • Serum Ferritin: Primary screening test for iron overload (should be monitored every 1-3 months). Goal: <1000 ng/mL.
  • Liver Function Tests (LFTs): ALT, AST, bilirubin, albumin (monitor for liver iron toxicity, hepatitis).
  • Cardiac MRI T2*: Gold standard for assessing cardiac iron loading (should be performed annually or biennially in TDT patients). Values <20 ms indicate iron overload; <10 ms indicates severe iron overload.
  • Endocrine Panel: Fasting glucose, HbA1c, thyroid function tests (TSH, free T4), parathyroid hormone, calcium, phosphate, vitamin D, sex hormones (LH, FSH, testosterone/estradiol, prolactin, IGF-1) – depending on age and clinical picture (annually from age 10 for TDT).
  • Viral Serology: For transfusion-transmitted infections (Hepatitis B, C, HIV) – annually.
  • Renal Function Tests: BUN, creatinine (especially with deferasirox use).

Imaging

• Recommended:
  • Skeletal X-rays: Skull (lateral view to show "hair-on-end" appearance), long bones (widened medullary spaces, cortical thinning, coarse trabeculae, signs of extramedullary hematopoiesis).
  • Echocardiography: To assess cardiac function (ejection fraction, ventricular dimensions) and evaluate for pulmonary hypertension (tricuspid regurgitant velocity). Essential for monitoring iron cardiomyopathy.
  • MRI T2: Specific for quantifying iron overload in the liver and heart. Liver iron concentration (LIC) >7 mg Fe/g dry weight indicates significant iron overload. LIC can also be measured by SQUID or biopsy, but MRI T2 is non-invasive and widely available.
• Advanced:
  • Bone Densitometry (DEXA scan): To assess bone mineral density and screen for osteoporosis, common in thalassemia patients due to marrow expansion, endocrine dysfunction, and chronic inflammation.
  • Abdominal Ultrasound: To assess liver and spleen size, detect gallstones, or evaluate for portal hypertension.
  • MRI of the Spine: If neurological symptoms suggest spinal cord compression from extramedullary hematopoiesis.

Management

Acute Management

• Immediate:
  • Blood Transfusion: For symptomatic anemia (pallor, fatigue, dyspnea) or to maintain target pre-transfusion hemoglobin levels.
    • For Thalassemia Major: Maintain pre-transfusion Hb level >9-10 g/dL.
    • For Hb H disease/Thalassemia Intermedia: Transfuse only for symptomatic anemia (Hb < 7 g/dL with symptoms or during stress), or if growth retardation, significant extramedullary hematopoiesis, or cardiac issues arise.
  • Management of Transfusion Reactions: Standard protocols for acute hemolytic, allergic, febrile non-hemolytic, or delayed reactions.
• Stabilization:
  • Correct severe anemia to optimize tissue oxygenation.
  • Initiate or adjust iron chelation therapy if iron overload is significant.
  • Address any acute infections promptly.
• Emergency:
  • Hyperhemolytic Crisis: Rare, but can occur during infections, leading to rapid drop in Hb. Requires immediate transfusion.
  • Acute Splenic Sequestration: More common in younger children. Rapid enlargement of spleen, severe anemia, hypovolemic shock. Requires immediate transfusion and fluid resuscitation. Splenectomy may be indicated after stabilization.
  • Cardiac Decompensation: Due to iron overload cardiomyopathy. Requires urgent intensive care, iron chelation, and management of heart failure (diuretics, inotropes).

Chronic Management

• Pharmacological:
  • Red Blood Cell Transfusions:
    • Standard of Care for Thalassemia Major. Regular transfusions suppress ineffective erythropoiesis, improve growth and development, prevent bone deformities, and reduce extramedullary hematopoiesis.
    • Frequency: Every 2-4 weeks.
    • Target: Maintain pre-transfusion Hb >9-10 g/dL.
    • Leukoreduced, CMV-negative, phenotype-matched blood should be used to reduce transfusion reactions and alloimmunization.
  • Iron Chelation Therapy (ICT): Essential for patients receiving chronic transfusions to prevent and treat iron overload-related organ damage. Initiated after approx. 10-20 units of blood or when serum ferritin consistently >1000 ng/mL.
    • Deferoxamine (DFO): (Desferal)
      • Route: Subcutaneous (SC) infusion (via pump) over 8-12 hours, 5-7 nights per week; or intravenous (IV) for severe overload or during hospitalization.
      • Dose: 25-50 mg/kg/day (up to 60 mg/kg/day in children with rapid iron accumulation).
      • Side Effects: Local reactions at infusion site, auditory/ocular toxicity (dose-dependent, monitor annually), growth retardation in children (ensure adequate dosage without overchelation), musculoskeletal pain.
    • Deferasirox (DFX): (Exjade, Jadenu)
      • Route: Oral, once daily. Dissolve dispersible tablets in water/juice or swallow film-coated tablets whole.
      • Dose: Initial 14-20 mg/kg/day for dispersible, 20-30 mg/kg/day for film-coated. Adjust based on ferritin/iron burden (max 40 mg/kg/day for dispersible, 30 mg/kg/day for film-coated).
      • Side Effects: Gastrointestinal upset (nausea, vomiting, diarrhea), skin rash, transient increase in serum creatinine (monitor monthly), liver enzyme elevations (monitor monthly). Rare: acute kidney injury, liver failure.
    • Deferiprone (DFP): (Ferriprox)
      • Route: Oral, three times daily.
      • Dose: 75-100 mg/kg/day.
      • Side Effects: Arthralgia, GI upset, transient transaminase elevations. Most serious: Agranulocytosis (monitor ANC weekly).
    • Combination Chelation: Often used for severe iron overload (e.g., cardiac iron) or in patients not responding to monotherapy (e.g., DFO + DFX or DFO + DFP).
  • Folic Acid Supplementation: 1 mg/day for all patients with chronic hemolysis to support erythropoiesis.
  • Hydroxyurea:
    • Indications: Primarily for Thalassemia Intermedia or Hb H disease to increase Hb F production, reduce ineffective erythropoiesis, and potentially decrease transfusion requirements. May also reduce splenomegaly and improve quality of life.
    • Dose: 10-20 mg/kg/day orally. Start low and titrate up.
    • Monitoring: CBC (WBC, platelets, Hb, MCV) to monitor for myelosuppression.
• Non-pharmacological:
  • Splenectomy:
    • Indications: Massive splenomegaly causing discomfort, hypersplenism leading to increased transfusion requirements (>200-250 mL/kg/year RBCs), severe leukopenia/thrombocytopenia, or intractable leg ulcers.
    • Pre-Splenectomy Care: Crucial vaccinations (Pneumococcal, Meningococcal, Hib) at least 2 weeks prior. Penicillin prophylaxis post-splenectomy (until adulthood).
    • Complications: Increased risk of sepsis (especially encapsulated bacteria), increased risk of thrombosis.
  • Hematopoietic Stem Cell Transplantation (HSCT):
    • Potential Cure for Thalassemia Major.
    • Indication: Best candidates are young patients (Class I or II criteria, Pesaro classification) with a matched sibling donor and no significant iron-related organ damage.
    • Outcome: High success rates (up to 80-90% cure) with matched sibling donors. Unrelated donor HSCT is also an option with lower but improving success rates.
  • Diet and Lifestyle: Avoid iron-rich foods. Vitamin C can enhance iron absorption, so consume cautiously (only with DFO, not with oral chelators). Maintain good hygiene, dental care.
  • Supportive Endocrine Management:
    • Growth hormone for severe growth failure.
    • Sex hormone replacement therapy for delayed puberty/hypogonadism.
    • Insulin for diabetes mellitus.
    • Thyroid hormone replacement for hypothyroidism.
    • Calcium and Vitamin D for hypoparathyroidism and osteoporosis.
    • Bisphosphonates for osteoporosis.
  • Viral Hepatitis Management: Prophylaxis (HBV vaccination), screening (HCV, HBV, HIV), and treatment if positive.
• Monitoring: (See Diagnostic Approach -> Laboratory Tests: Monitoring for details and frequency)
  • Regular assessment of anemia and transfusion needs.
  • Strict monitoring of iron overload (ferritin, MRI T2*).
  • Evaluation of organ function (cardiac, liver, endocrine).
  • Screening for complications (bone health, gallstones).
  • Psychosocial assessment and support.

Treatment Algorithms

• First-Line:
  • Beta-Thalassemia Major: Lifelong regular blood transfusions + meticulous iron chelation therapy. Folic acid supplementation.
  • Beta-Thalassemia Intermedia/Non-transfusion Dependent Thalassemia (NTDT): Folic acid supplementation. Careful monitoring for iron overload (often due to increased GI absorption) and complications. Hydroxyurea may be used to reduce anemia severity and complications. Transfusion support as needed. Chelation is initiated if ferritin >800-1000 ng/mL, or significant organ iron.
  • Hb H Disease: Folic acid supplementation. Avoid oxidative stressors. Transfusions only for significant symptomatic anemia. Splenectomy if massive splenomegaly or high transfusion requirement.
  • Thalassemia Trait: No specific treatment needed. Genetic counseling.
• Second-Line:
  • Hematopoietic Stem Cell Transplantation (HSCT): For eligible patients with Beta-Thalassemia Major (especially Class I or II Pesaro risk score).
  • Splenectomy: For transfusion-dependent patients with hypersplenism or massive splenomegaly.
• Refractory Cases:
  • Aggressive Combination Chelation Regimens: For severe, refractory iron overload, especially cardiac.
  • New Therapies:
    • Luspatercept: Erythroid maturation agent, approved for beta-thalassemia requiring regular transfusions, shown to reduce transfusion burden.
    • Gene Therapy: Investigational. Involves introducing a functional globin gene into the patient's hematopoietic stem cells. Initial clinical trials show promising results with potential for transfusion independence.
  • Management of Specific Complications: Tailored approaches for cardiac failure, liver failure, endocrine dysfunction, bone issues.

Complications

• Common:
  • Iron Overload: Liver (fibrosis, cirrhosis, liver failure), heart (cardiomyopathy, arrhythmias, heart failure), endocrine glands (diabetes, hypogonadism, hypothyroid, hypoparathyroid, growth failure).
  • Splenomegaly/Hypersplenism: Can lead to increased transfusion requirements and pancytopenia.
  • Gallstones: Due to chronic hemolysis (pigmented stones).
  • Bone Disease: Osteoporosis, osteopenia, bone pain, pathological fractures due to marrow expansion and endocrine dysfunction.
  • Growth Retardation and Delayed Puberty.
  • Leg Ulcers: More common in NTDT.
• Serious:
  • Cardiac Failure: Leading cause of death in inadequately chelated transfusion-dependent patients.
  • Liver Cirrhosis and Failure.
  • Severe Infections: Especially post-splenectomy sepsis (often fatal).
  • Thrombosis: Increased risk of venous thromboembolism (DVT, PE), particularly in splenectomized NTDT patients.
  • Extramedullary Hematopoiesis: Can cause spinal cord compression, nerve impingement, or tumor-like masses in unusual sites.
• Long-term:
  • Endocrine dysfunction (as listed above, requiring lifelong hormone replacement).
  • Pulmonary Hypertension.
  • Renal impairment (can be related to iron overload or chelation toxicity).
  • Psychosocial burden, impact on quality of life.

Prognosis

• Factors:
  • Type and Severity of Thalassemia: Thalassemia major historically had poor prognosis without treatment.
  • Adherence to Treatment: Consistent blood transfusions and meticulous iron chelation therapy are paramount.
  • Monitoring for Complications: Early detection and aggressive management of iron overload and other complications.
  • Access to Specialized Care: Comprehensive thalassemia centers provide better outcomes.
  • Success of Curative Therapies: HSCT offers the best long-term outcome for eligible patients.
• Survival:
  • Untreated Thalassemia Major: Death typically occurs by age 5-10 years due to severe anemia and iron overload.
  • Treated Thalassemia Major: With modern management (regular transfusions, effective chelation), survival into adulthood is common, with many patients living into their 50s and beyond. Cardiac complications remain the leading cause of mortality.
  • Thalassemia Intermedia: Varies widely. Many patients live long lives, but they are still at risk for chronic complications such as iron overload, thrombosis, and pulmonary hypertension.
• Quality of Life: Can be significantly impacted by the chronic nature of the disease, frequent transfusions, chelation regimen side effects, and complications. However, improvements in medical management have generally improved quality of life. Psychosocial support is crucial.

Prevention

• Primary:
  • Genetic Counseling: For couples at risk (e.g., both partners are carriers) to understand the inheritance pattern and risks to offspring.
  • Premarital and Preconception Screening: Population-based screening programs in high-prevalence areas to identify carriers before marriage or pregnancy.
  • Prenatal Diagnosis: For high-risk pregnancies, chorionic villus sampling (CVS) (10-14 weeks gestation) or amniocentesis (15-20 weeks gestation) can diagnose severe thalassemia syndromes (e.g., Hb Bart's hydrops fetalis, beta-thalassemia major). This allows for informed decisions regarding selective termination of affected fetuses.
• Secondary:
  • Early Diagnosis: Newborn screening or early childhood diagnosis of severe thalassemia types allows for prompt initiation of transfusions and chelation, preventing severe complications and improving long-term outcomes.
  • Carrier Screening: Screening of family members once a patient is diagnosed.
• Tertiary:
  • Prevention of Complications: This is the focus of chronic management, including meticulous iron chelation to prevent organ damage, vaccination against infections (especially post-splenectomy), and regular monitoring for early detection and management of complications.

Special Populations

• Pediatric:
  • Growth and Development: Close monitoring is crucial. Growth retardation is common. Endocrine evaluation from age 10-12.
  • Transfusion Regimen: Tailored to maintain growth and suppress erythropoietic activity.
  • Chelation: Careful dosing to balance iron removal with potential side effects (e.g., growth plate toxicity with high-dose DFO). Transition to oral chelators as appropriate.
  • Psychosocial Support: For children and families coping with a chronic illness.
  • HSCT: More favorable outcomes in younger, less iron-overloaded children.
• Geriatric:
  • Management often complicated by accumulated organ damage from iron overload (cardiac, liver, endocrine).
  • Increased risk of osteoporosis, thrombosis, and secondary malignancies.
  • Polypharmacy and drug interactions need careful consideration.
• Pregnancy:
  • Thalassemia Minor: Generally uncomplicated, but monitor for iron deficiency (which can co-exist).
  • Thalassemia Major/Intermedia: High-risk pregnancy requiring multidisciplinary care.
    • Increased Transfusion Needs: Due to expanding blood volume and fetal demands.
    • Cardiac Monitoring: Especially if pre-existing cardiomyopathy. Increased cardiac burden during pregnancy.
    • Chelation: Deferoxamine is generally considered safer during pregnancy (Category B), especially after the first trimester. Deferasirox and Deferiprone are generally contraindicated.
    • Fetal Risks: For alpha-thalassemia major, severe hydrops fetalis is almost always fatal. For beta-thalassemia, careful monitoring of fetal growth and well-being.
• Comorbidities:
  • Diabetes Mellitus: Requires careful glycemic control and specific insulin regimens.
  • Hypothyroidism: Requires thyroid hormone replacement.
  • Hypogonadism: Requires sex hormone replacement therapy.
  • Osteoporosis: Requires calcium, vitamin D, and often bisphosphonates.
  • Viral Hepatitis: Aggressive treatment of Hepatitis C/B is crucial to prevent progression to cirrhosis in already iron-overloaded livers.

Clinical Pearls

• Diagnostic:
  • Always consider thalassemia in patients with microcytic, hypochromic anemia that is unresponsive to iron supplementation, especially if iron studies are normal or elevated.
  • A normal or elevated red blood cell count in the presence of low MCV/MCH is a key differentiator from iron deficiency anemia.
  • Hemoglobin electrophoresis/HPLC with elevated Hb A2 is the cornerstone for diagnosing beta-thalassemia trait.
  • DNA testing is required for definitive diagnosis of alpha-thalassemia.
• Treatment:
  • Iron chelation is as critical as blood transfusion for long-term survival in transfusion-dependent thalassemia. Non-adherence is a major challenge.
  • Regular cardiac MRI T2* is essential for monitoring cardiac iron, which is the most critical organ for prognosis. Ferritin alone is insufficient.
  • Hydroxyurea can significantly benefit many patients with non-transfusion-dependent thalassemia and some with Hb H disease by reducing anemia and complications.
  • Post-splenectomy patients require lifelong penicillin prophylaxis and careful monitoring for signs of infection.
• Pitfalls:
  • Misdiagnosis as Iron Deficiency Anemia: Leading to inappropriate and potentially harmful iron supplementation, exacerbating iron overload.
  • Inadequate Iron Chelation: Results in progressive and irreversible organ damage, particularly cardiac and liver failure.
  • Overlooking Endocrine Complications: These are common and require active screening and management to improve quality of life and long-term health.
  • Ignoring Psychosocial Aspects: The chronic nature of the disease and treatment burden can significantly impact quality of life and mental health.

Recent Updates

• Guidelines: The Thalassaemia International Federation (TIF) regularly updates its comprehensive guidelines for the management of thalassemia, serving as a key global reference. American Society of Hematology (ASH) also publishes guidelines.
• Evidence:
  • Gene Therapy: Significant progress in clinical trials for both beta-thalassemia and sickle cell disease. Lentiviral vector-mediated gene therapy (e.g., LentiGlobin, now approved as betibeglogene autotemcel/Zynteglo) has shown the potential for transfusion independence in a subset of patients. CRISPR/Cas9-based gene editing is also in trials. These therapies hold promise for a one-time curative treatment but are very expensive and have long-term safety data still accumulating.
  • Luspatercept (Reblozyl): Approved in 2019 by FDA and EMA for beta-thalassemia patients requiring regular red blood cell transfusions. It is an erythroid maturation agent that promotes differentiation of late-stage erythroid precursors, leading to more effective erythropoiesis and reduced transfusion burden in a significant proportion of patients.
  • New Oral Chelators and Combinations: Ongoing research into optimizing chelation regimens, including new oral agents and combination strategies for better efficacy and safety profiles.
• Controversies:
  • Optimal Chelation Strategy: Debate continues regarding the optimal choice of chelator, monotherapy vs. combination therapy, and personalized dosing based on iron burden and specific organ involvement.
  • Role of Gene Therapy: While promising, the long-term efficacy, safety, accessibility, and cost-effectiveness of gene therapy in routine clinical practice for a wider patient population are still under evaluation.
  • Management of Non-Transfusion Dependent Thalassemia (NTDT): Specific guidelines for iron overload management in NTDT, where increased GI absorption is the primary cause, differ from TDT. There's ongoing discussion about prophylactic chelation in NTDT.
  • Thrombosis Risk: Better understanding and management strategies for the hypercoagulable state and thrombotic complications, especially in splenectomized NTDT patients.

Key References

• Guidelines:
  • Thalassaemia International Federation (TIF) International Guidelines for the Management of Thalassemia: Regularly updated, comprehensive, and globally recognized. Available at www.thalassaemia.org.cy.
  • American Society of Hematology (ASH) Clinical Practice Guidelines for Thalassemia.
• Studies:
  • Major clinical trials for iron chelators (e.g., the EPIC study for deferasirox, studies evaluating combination chelation regimens).
  • Landmark studies on hematopoietic stem cell transplantation for thalassemia.
  • Recent clinical trials on gene therapy for beta-thalassemia (e.g., Northstar, HGB-204, HGB-205, HGB-207 studies).
  • Studies on Luspatercept for beta-thalassemia (e.g., BELIEVE trial).
• Reviews:
  • Comprehensive reviews published in high-impact hematology journals such as Blood, Lancet Haematology, New England Journal of Medicine, and Haematologica.
  • UpToDate: Thalassemia overview, diagnosis, and management sections.